Paul E Brenchley

List of Publications by Year
in descending order

61	4,186	279487 23	149479 56
papers	citations	h-index	g-index

62	62	62	4538
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Peptide <scp>GAM</scp> immunoadsorption in <scp>antiâ€PLA₂R</scp> positive autoimmune membranous nephropathy. The <scp>PRISM</scp> trial. Journal of Clinical Apheresis, 2022, 37, 40-53.	0.7	3
2	Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
3	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. Kidney International, 2021, 99, 671-685.	2.6	24
4	Identification of a Locus on the X Chromosome Linked to Familial Membranous Nephropathy. Kidney International Reports, 2021, 6, 1669-1676.	0.4	3
5	The investigative burden of membranous nephropathy in the UK. CKJ: Clinical Kidney Journal, 2020, 13, 27-34.	1.4	6
6	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	5.8	120
7	The anti-PLA2R antibody in membranous nephropathy: what we know and what remains aÂdecade after its discovery. Kidney International, 2019, 96, 1292-1302.	2.6	97
8	Primary Membranous Nephropathy as a Model of Autoimmune Disease. , 2019, , .		0
9	Genetics of membranous nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 1493-1502.	0.4	22
10	Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrology Dialysis Transplantation, 2018, 33, 2145-2155.	0.4	15
11	Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in antiâ€PLA₂R positive primary membranous nephropathy. Journal of Clinical Apheresis, 2018, 33, 283-290.	0.7	10
12	Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrology Dialysis Transplantation, 2017, 32, 325-332.	0.4	63
13	Membranous nephropathy: integrating basic science into improved clinical management. Kidney International, 2017, 91, 566-574.	2.6	160
14	Membranous nephropathy: thinking through the therapeutic options. Nephrology Dialysis Transplantation, 2017, 32, i22-i29.	0.4	35
15	PLA2R binds to the annexin A2-S100A10 complex in human podocytes. Scientific Reports, 2017, 7, 6876.	1.6	22
16	Time to recovery from haemodialysis : location, intensity and beyond. Nephrology, 2016, 21, 1017-1026.	0.7	11
17	Healthcare decision-making in end stage renal disease-patient preferences and clinical correlates. BMC Nephrology, 2015, 16, 189.	0.8	19
18	Self-Cannulation for Haemodialysis: Patient Attributes, Clinical Correlates and Self-Cannulation Predilection Models. PLoS ONE, 2015, 10, e0125606.	1.1	7

#	Article	IF	Citations
19	A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis. International Journal of Nephrology, 2015, 2015, 1-12.	0.7	5
20	FP123RESULTS OF SURVEY ON MANAGEMENT OF MEMBRANOUS NEPHROPATHY IN UNITED KINGDOM *ON BEHALF OF UK MN RADAR STEERING GROUP. Nephrology Dialysis Transplantation, 2015, 30, iii108-iii108.	0.4	2
21	FP424COMPARISON OF TWO FGF23 ELISA KITS. Nephrology Dialysis Transplantation, 2015, 30, iii211-iii212.	0.4	0
22	FP432TREATMENT WITH ORAL PHOSPHATE BINDERS TO A LOW TARGET PHOSPHATE DECREASES FGF23 LEVELS IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii215-iii215.	0.4	0
23	Acute Arteriovenous Access Failure: Long-Term Outcomes of Endovascular Salvage and Assessment of Co-Variates Affecting Patency. Nephron, 2015, 129, 241-246.	0.9	11
24	Genetic Polymorphisms and Peritoneal Membrane Function. Peritoneal Dialysis International, 2015, 35, 517-529.	1.1	12
25	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron, 2015, 130, 159-168.	0.9	49
26	Prospective controlled pilot study of arteriovenous fistula placement using the novel Optiflow device. Journal of Vascular Surgery, 2015, 61, 1020-1025.	0.6	27
27	rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial. BMC Research Notes, 2015, 8, 21.	0.6	8
28	Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 302-313.	3.0	185
29	Global Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix. Journal of the American Society of Nephrology: JASN, 2014, 25, 939-951.	3.0	158
30	Towards radiological diagnosis of abdominal adhesions based on motion signatures derived from sequences of cine-MRI images. Physica Medica, 2014, 30, 437-447.	0.4	11
31	Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1386-1392.	2.2	152
32	The genetic contribution to recurrent autoimmune nephritis. Transplantation Reviews, 2014, 28, 140-144.	1.2	1
33	Transforming growth factor Î²-induced peritoneal fibrosis is mouse strain dependent*. Nephrology Dialysis Transplantation, 2013, 28, 2015-2027.	0.4	27
34	Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney International, 2013, 83, 940-948.	2.6	287
35	Barriers to successful implementation of care in home haemodialysis (BASIC-HHD):1. Study design, methods and rationale. BMC Nephrology, 2013, 14, 197.	0.8	18
36	The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis and Tissue Repair, 2013, 6, 18.	3.4	110

#	Article	IF	Citations
37	Subcutaneous interstitial pressure and volume characteristics in renal impairment associated with edema. Kidney International, 2013, 84, 980-988.	2.6	46
38	Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 677-683.	3.0	108
39	Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. Nephrology Dialysis Transplantation, 2012, 27, 2502-2510.	0.4	23
40	Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1735-1743.	3.0	270
41	Development of Novel Single-Stranded Nucleic Acid Aptamers against the Pro-Angiogenic and Metastatic Enzyme Heparanase (HPSE1). PLoS ONE, 2012, 7, e37938.	1.1	22
42	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	13.9	820
43	Reverse iontophoresis of urea in health and chronic kidney disease: a potential diagnostic and monitoring tool?. European Journal of Clinical Investigation, 2012, 42, 840-847.	1.7	15
44	Measuring the thickness of the peritoneal membrane in mice with optical coherence tomography. Proceedings of SPIE, 2011, , .	0.8	0
45	Initial Observations using a Novel â€œCineâ€•Magnetic Resonance Imaging Technique to Detect Changes in Abdominal Motion Caused by Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2011, 31, 287-290.	1.1	19
46	A Modified in vivo Flow Variation Technique of Microdialysis for Sampling Uremic Toxins in the Subcutaneous Interstitial Compartment. Blood Purification, 2011, 32, 96-103.	0.9	7
47	Risk HLA-DQA1 and PLA₂R1 Alleles in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 2011, 364, 616-626.	13.9	442
48	Immunosuppression Is Essential for Successful Allogeneic Transplantation of the Metanephros. Transplantation, 2009, 88, 151-159.	0.5	14
49	Development and functional capacity of transplanted rat metanephroi. Nephrology Dialysis Transplantation, 2007, 23, 871-879.	0.4	21
50	The Emergence of Networks in Human Genome Epidemiology. Epidemiology, 2007, 18, 1-8.	1.2	102
51	A road map for efficient and reliable human genome epidemiology. Nature Genetics, 2006, 38, 3-5.	9.4	244
52	Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes. Diabetes, 2004, 53, 861-864.	0.3	170
53	Mechanisms of disease: angiogenesis, vascular endothelial growth factor (VEGF) and psoriasis. Journal of the American Academy of Dermatology, 2004, 50, P146.	0.6	3
54	Inhibition of chronic vascular rejection by donor-specific blood transfusion is associated with a reduction in transforming growth factor-??1 expression1. Transplantation, 2002, 73, 1573-1581.	0.5	7

#	Article	IF	Citations
55	Recent Approaches to Understanding Clinical Glomerular Disease. Renal Failure, 1996, 18, 705-709.	0.8	0
56	Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney International, 1995, 48, 1953-1958.	2.6	51
57	Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney International, 1992, 41, 933-937.	2.6	72
58	Detection of antiâ€epithelial cell antibodies in association with pediatric renal transplant failure using a novel microcytotoxicity assay. Tissue Antigens, 1991, 37, 152-155.	1.0	16
59	Some factors affecting the quantitation of rheumatoid factors by enzyme immunoassay. Journal of Immunological Methods, 1983, 65, 343-350.	0.6	4
60	Frequent elevation of tissue polypeptide antigen in the sera of workers exposed to bladder carcinogens. International Journal of Cancer, 1978, 22, 542-545.	2.3	18
61	Connective-Tissue Glycoconjugates of Bovine Tendon and Skin. Biochemical Society Transactions, 1977, 5, 431-433.	1.6	2